Inventage Lab
인벤티지랩 · 389470
Industrials Commercial Services · KOSDAQ
Market cap US$479.3M (₩661.4B)
Overview
Inventage Lab develops drug delivery technology, systems that control how and how long a medicine is released inside the body after injection.
Its platforms serve pharmaceutical companies and biotechs that need long-acting injectable formulations, genetic medicines such as mRNA vaccines, and biologic drugs that it helps convert from intravenous to under-the-skin delivery. Listed on KOSDAQ, Korea's tech-focused stock exchange, the company pursues revenue through a combination of licensing its platform technology to partners, co-developing drug candidates, and providing contract development and manufacturing services.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$476.9K
- FY2024US$1.3M
- FY2025US$2.1M
Operating profit
- FY2023−US$11.6M
- FY2024−US$13.7M
- FY2025−US$20.6M
Net income
- FY2023−US$19.6M
- FY2024−US$12.3M
- FY2025−US$11.5M
Key ratios (FY2025)
Why it matters
A named subsidiary, Curatis, holds dedicated GMP-certified manufacturing facilities for long-acting injectables and gene-therapy or mRNA vaccine production that underpin the contract manufacturing business.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?